NervGen Pharma (TSE:NGEN) has released an update.
NervGen Pharma is progressing their new drug candidate, NVG-300, aimed at treating ischemic stroke, ALS, and spinal cord injury, into the preclinical proof-of-concept stage after demonstrating efficacy in a severe SCI model. The molecule holds the promise of a new treatment option with potential market exclusivity post-approval, given its expected intellectual property protection extending beyond 2040. NVG-300, which is part of a growing pipeline of neurologic solutions, is also being developed for self-administration in a prefilled syringe format.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
